Oncolytic Virotherapy Market Size & Growth Forecast 2027–2036, By Segments (Virus Type, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Oncolytic Virotherapy Market size was over USD 37.95 million in 2026 and is likely to grow at a 23.04% CAGR between 2027 and 2036, reaching USD 301.77 million by 2036. The industry revenue for 2027 is estimated at USD 46.21 million.

• Base Year Value (2026): USD 37.95 million
• CAGR (2027-2036): 23.04%
• Forecast Year Value (2036): USD 301.77 million
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Oncolytic Virotherapy Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads because of its advanced oncology ecosystem, strong biopharmaceutical innovation, established clinical research infrastructure, and active cancer immunotherapy development.
  • Asia Pacific is projected to expand at a 28.16% CAGR, supported by rising oncology research, expanding healthcare capabilities, greater clinical development participation, and increasing adoption of advanced cancer therapies.

• Segment Momentum:

  • Genetically Engineered Oncolytic viruses are the largest and fastest-growing segment because they offer optimized tumor selectivity, therapeutic payload delivery, and adaptable designs that support evolving oncology treatment strategies.
  • Solid Tumors are expanding fastest as development programs broaden virotherapy use beyond traditional indications, creating greater commercial and clinical opportunities across larger patient populations.

• Market Expansion Drivers:

  • Rising global cancer burden increasing demand for advanced targeted gene-based therapies.
  • Expanding clinical trials combining oncolytic viruses with immunotherapy accelerating treatment innovation.
  • Increasing government and institutional research funding supporting commercialization of virotherapy platforms.

• Leading Market Participants:

  Major companies in the oncolytic virotherapy market include Amgen Inc. (United States), Takara Bio Inc. (Japan), Transgene SA (France), Shanghai Sunway Biotech Co., Ltd. (China), Pfizer Inc. (United States), Calidi Biotherapeutics, Inc. (United States), Lokon Pharma AB (Sweden), TILT Biotherapeutics Ltd. (Finland), CG Oncology, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 37.95 million
  • 2027 Estimated Market Size: USD 46.21 million.
  • Projected Market Size: USD 301.77 million by 2036
  • Growth Forecasts: 23.04% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Genetically Engineered Oncolytic (Virus Type) | Melanoma (Application) | Hospitals (End-use)
  • Emerging Opportunity Segment: Genetically Engineered Oncolytic (Virus Type) | Solid Tumors (Application) | Specialty Clinics (End-use)

Market Growth Drivers and Industry Trends

Rising global cancer burden increasing demand for advanced targeted gene-based therapies

The growing prevalence of cancer worldwide is creating a substantial need for treatment approaches capable of selectively targeting malignant cells, supporting the expansion of the oncolytic virotherapy market. Oncolytic viruses are designed to preferentially infect and destroy cancer cells while also stimulating immune responses against tumors, offering a distinct therapeutic mechanism compared with conventional cancer treatments. Increasing recognition of tumor heterogeneity and the limitations associated with existing treatment modalities is encouraging researchers and clinicians to explore gene-based and biologically targeted approaches for cancers that remain difficult to treat with standard therapies.

Expanding clinical trials combining oncolytic viruses with immunotherapy accelerating treatment innovation

Combination treatment strategies are becoming an important area of oncology research, and the oncolytic virotherapy market is benefiting from increasing clinical investigation of oncolytic viruses alongside immunotherapies. Oncolytic viruses can modify the tumor microenvironment and promote immune activation, potentially improving the ability of immune-based therapies to recognize and attack cancer cells. Clinical studies evaluating combinations with immune checkpoint inhibitors and other immunomodulatory approaches are therefore expanding the therapeutic potential of virotherapy platforms while generating evidence on dosing, safety, treatment sequencing, and patient selection.

Increasing government and institutional research funding supporting commercialization of virotherapy platforms

Greater public and institutional investment in cancer research is strengthening the oncolytic virotherapy market by providing financial support for the development, validation, and manufacturing of advanced virotherapy technologies. Research funding can help investigators progress promising viral platforms from laboratory studies through preclinical development and clinical evaluation, while institutional support contributes to research infrastructure and specialized capabilities required for complex biological therapies. Continued funding across areas such as viral engineering, tumor targeting, manufacturing processes, and clinical development can also help address technical barriers associated with bringing oncolytic therapies into broader clinical use.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global cancer burden increasing demand for advanced targeted gene-based therapies	2.00%	High	North America, Europe	High	Mid Term
Expanding clinical trials combining oncolytic viruses with immunotherapy accelerating treatment innovation	1.90%	High	North America, Asia Pacific	Emerging	Long Term
Increasing government and institutional research funding supporting commercialization of virotherapy platforms	1.60%	High	Europe, North America	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest position in the oncolytic virotherapy market in 2026, reflecting its advanced oncology infrastructure, strong research ecosystem, and growing adoption of innovative cancer treatment approaches. The region has a well-established clinical environment for developing and evaluating novel immuno-oncology therapies, while increasing interest in targeted treatment strategies is encouraging the exploration of virus-based approaches that can selectively attack tumor cells and stimulate immune responses. Strong investment in biotechnology research, specialized cancer centers, and advanced clinical capabilities supports continued development and adoption. Growing emphasis on personalized and immune-based cancer care further contributes to the region's market leadership.

Asia Pacific is the fastest-growing region, supported by expanding oncology care infrastructure, rising cancer treatment needs, and increasing investment in advanced biopharmaceutical research. Healthcare systems across the region are progressively adopting innovative therapeutic approaches as access to specialized cancer services improves. Greater participation in clinical research, development of biotechnology capabilities, and increasing collaboration across healthcare and research institutions are creating a stronger environment for oncolytic virotherapy. At the same time, rising awareness of immunotherapy and targeted cancer treatment is supporting demand for emerging therapeutic options, strengthening the region's growth potential.

Key Country Insights

United States

Clinical Innovation Hub

The U.S. continues to prioritize advanced oncology research through extensive clinical trial activity and collaboration between biotechnology firms and cancer centers. Regulatory experience and investment in novel immunotherapies support broader development of oncolytic virotherapy platforms.

Japan

Precision Oncology Integration

Japan is integrating oncolytic virotherapy into precision oncology initiatives supported by advanced molecular diagnostics. Japanese developers are exploring combination therapies with immune checkpoint inhibitors to improve treatment outcomes for selected patient populations.

South Korea

Biotech Development Pipeline

South Korea is strengthening its biotechnology ecosystem with investments in viral vector technologies and cancer immunotherapy research. Local companies are advancing clinical development programs while collaborating with international partners to expand commercialization opportunities.

Germany

Translational Research Focus

Germany emphasizes translational oncology programs that connect academic discoveries with commercial therapeutic development. German research institutions and biopharmaceutical companies are expanding partnerships to evaluate oncolytic virotherapy across multiple solid tumor indications.

France

Academic Collaboration Network

France supports oncolytic virotherapy through coordinated academic research and hospital-based oncology programs. French institutions are evaluating innovative viral therapies alongside established cancer treatments to broaden therapeutic options within clinical practice.

Italy

Hospital Research Expansion

Italy is increasing participation in multicenter oncology studies that include investigational oncolytic virotherapy treatments. Italian healthcare institutions are focusing on improving patient access to innovative cancer therapies through collaborative clinical research initiatives.

Segment Leadership and Growth Trends

 

Virus Type Segment Analysis: Genetically Engineered Oncolytic (Largest & Fastest-Growing Segment)

Genetically engineered oncolytic segment accounted for both the largest and fastest-growing share of the oncolytic virotherapy market in 2026, reflecting the growing importance of engineered viruses designed to selectively target and destroy cancer cells. Genetic modification can enhance viral tumor selectivity, improve therapeutic activity, and enable incorporation of mechanisms intended to stimulate antitumor immune responses. Continued advances in cancer biology and genetic engineering are supporting the development of increasingly sophisticated oncolytic therapies. Growing interest in targeted and immune-mediated cancer treatment is further strengthening the segment's market position.

Application Segment Analysis: Melanoma (Largest Segment) vs Solid Tumors (Fastest-Growing Segment)

Melanoma segment held the largest share of the oncolytic virotherapy market in 2026, supported by the clinical relevance of oncolytic approaches in treating melanoma and the segment's role in the development and adoption of virus-based cancer therapies. Melanoma provides an important application area for therapies designed to selectively target malignant cells while stimulating immune responses against tumors. Continued innovation in cancer immunotherapy and growing interest in treatment approaches that can complement existing therapeutic strategies are supporting demand in this application. The established clinical focus on melanoma therefore continues to contribute to its leading position.

Solid tumors are the fastest-growing application segment, driven by expanding research into the use of oncolytic viruses across a broader range of difficult-to-treat cancers. Solid tumors represent a substantial therapeutic opportunity because engineered viruses can potentially be designed to target tumor cells while activating localized and systemic immune responses. Increasing investment in innovative cancer therapies and advances in tumor-specific targeting are encouraging broader investigation of oncolytic virotherapy beyond established applications. The pursuit of more effective treatment options for diverse solid malignancies is consequently creating significant growth opportunities for this segment.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Virus Type	Genetically Engineered Oncolytic, Oncolytic Wild-Type Viruses	Genetically Engineered Oncolytic	Genetically Engineered Oncolytic
Application	Solid Tumors, Melanoma	Melanoma	Solid Tumors
End-use	Hospitals, Specialty Clinics, Cancer Research Institutes	Hospitals	Specialty Clinics

Competitive Landscape and Market Positioning

Top players in the oncolytic virotherapy market:

1. Amgen Inc. (United States)

2. Takara Bio Inc. (Japan)

3. Transgene SA (France)

4. Shanghai Sunway Biotech Co. Ltd. (China)

5. Pfizer Inc. (United States)

6. Calidi Biotherapeutics Inc. (United States)

7. Lokon Pharma AB (Sweden)

8. TILT Biotherapeutics Ltd. (Finland)

9. CG Oncology Inc. (United States)

The oncolytic virotherapy market is progressing through advanced immunotherapy research and targeted viral engineering approaches. Collaborative innovation networks are accelerating clinical development and trial expansion. New therapy introductions reflect growing focus on precision oncology solutions. Strengthened research ecosystems are enabling faster translation from laboratory innovation to clinical application.

Industry Development/News

Company Name	Date	Key Development
UroGen Pharma	Feb-26	UroGen Pharma acquired key assets related to the oncolytic virus ICVB-1042 from IconOVir Bio, Inc. This strategic acquisition expands UroGen’s clinical pipeline, reflecting an industry-wide trend of consolidating high-potential virotherapy assets to address unmet needs in targeted cancer treatment and enhancing the company's competitive position in the immunotherapy space.
Calidi Biotherapeutics	Aug-25	Calidi Biotherapeutics received FDA Fast Track designation for CLD-201, an investigational oncolytic virus therapy targeting soft tissue sarcoma. This regulatory milestone accelerates the clinical development pathway for the candidate, providing a streamlined framework for regulatory interaction and underscoring the therapy's potential to address significant medical gaps in aggressive oncology indications.
Genelux Corporation	Jun-26	Genelux Corporation initiated a Phase 1b/2 clinical study to evaluate the safety and anti-tumor activity of its proprietary Olvi-Vec oncolytic immunotherapy in patients with recurrent or refractory ovarian cancer. This progression into mid-stage clinical trials marks a significant operational step toward validating the efficacy of its virotherapy platform in complex, difficult-to-treat solid tumor segments.
SillaJen Inc.	Jun-26	SillaJen Inc. announced the commencement of a Phase 3 study for its vaccinia virus-based immunotherapy, Pexa-Vec, in combination with sorafenib for advanced hepatocellular carcinoma. By advancing to late-stage pivotal testing, this initiative represents a major commitment to establishing a new standard-of-care regimen and demonstrates the commercial scalability of the company’s lead therapeutic candidate.
Imugene	Nov-24	Imugene reported sustained complete response data in a patient with bile tract cancer from its Phase I MAST trial, with the patient remaining in remission for over two years. This long-term clinical outcome provides robust evidence supporting the durability and therapeutic potential of Imugene’s oncolytic virotherapy approach in addressing complex gastrointestinal malignancies.
Tomahawk Oncology	Jul-24	Tomahawk Oncology entered an exclusive licensing agreement with the University of Houston to commercialize proprietary cancer therapeutic technology. This strategic partnership broadens the company’s oncology research portfolio, positioning it to integrate new virotherapy-relevant assets into its development pipeline and enhancing its long-term research and development capabilities in the cancer immunotherapy market.